MADLID - Machine Learning Driven Liquid Biopsy Biomarker Discovery Platform

Liquid biopsies-derived biomarkers have shown robust and promising efficacy for diagnosing and monitoring various diseases in a minimally invasive manner as we have seen in recent disease pandemics such as COVID-19 and cancer. However, sensitivity and specificity are one of the biggest issues associated with the current state-of-the-art approaches based on the detection of cell-free biomarkers such as nucleic acids, cytokines, and soluble antibodies. These issues are critical hurdles for physicians to fully harness the benefits of liquid biopsies in their diagnostics and treatment decisions. To tackle this, our novel discovery platform applies advanced machine learning to analyze tissues-specific extracellular vesicles (EVs) in our body to unleash the maximum potential of liquid biopsies diagnostics, real-time disease monitoring, and advanced artificial intelligence to enable reliable and personalized health monitoring and treatments.